61 related articles for article (PubMed ID: 10860010)
1. [Pharmacoepidemiology: definitions, problems, methodology].
Bégaud B; Dangoumau J
Therapie; 2000; 55(1):113-7. PubMed ID: 10860010
[TBL] [Abstract][Full Text] [Related]
2. Epidemiologic studies of adverse effects of anti-retroviral drugs: how well is statistical power reported.
Halpern SD; Barton TD; Gross R; Hennessy S; Berlin JA; Strom BL
Pharmacoepidemiol Drug Saf; 2005 Mar; 14(3):155-61. PubMed ID: 15624138
[TBL] [Abstract][Full Text] [Related]
3. Validity of chronic drug exposure presumed from repeated patient interviews varied according to drug class.
Noize P; Bazin F; Pariente A; Dufouil C; Ancelin ML; Helmer C; Moore N; Fourrier-Réglat A
J Clin Epidemiol; 2012 Oct; 65(10):1061-8. PubMed ID: 22819646
[TBL] [Abstract][Full Text] [Related]
4. Presence of pharmacoepidemiology in three bibliographic databases: Medline, IPA and SCI.
Arrebola-Pascual I; García-López JA
Pharmacoepidemiol Drug Saf; 2002 Sep; 11(6):499-502. PubMed ID: 12426935
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacoepidemiology of antiepileptic drugs in children: comparative analysis of drug effectiveness and safety].
Gamirova RG; Ziganshina LE
Eksp Klin Farmakol; 2008; 71(6):3-7. PubMed ID: 19140506
[TBL] [Abstract][Full Text] [Related]
6. Pharmacoepidemiology studies: what levels of evidence and how can they be reached?
Lapeyre-Mestre M; Sapède C; Moore N; ; Bilbault P; Blin P; Chopy D; Evans D; Gueyffier F; Lacoin L; Malbezin M; Micallef J; Morlet-Vigier D; Muller S; Oger E; Plétan Y; Pons G; Verpillat P; Vigneau C
Therapie; 2013; 68(4):241-52. PubMed ID: 23981262
[TBL] [Abstract][Full Text] [Related]
7. Comparison of health insurance claims and patient interviews in assessing drug use: data from the Three-City (3C) Study.
Noize P; Bazin F; Dufouil C; Lechevallier-Michel N; Ancelin ML; Dartigues JF; Tzourio C; Moore N; Fourrier-Réglat A
Pharmacoepidemiol Drug Saf; 2009 Apr; 18(4):310-9. PubMed ID: 19241438
[TBL] [Abstract][Full Text] [Related]
8. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
9. Using propensity scores subclassification to estimate effects of longitudinal treatments: an example using a new diabetes medication.
Segal JB; Griswold M; Achy-Brou A; Herbert R; Bass EB; Dy SM; Millman AE; Wu AW; Frangakis CE
Med Care; 2007 Oct; 45(10 Supl 2):S149-57. PubMed ID: 17909374
[TBL] [Abstract][Full Text] [Related]
10. A quantitative approach to benefit-risk assessment of medicines - part 1: the development of a new model using multi-criteria decision analysis.
Mussen F; Salek S; Walker S
Pharmacoepidemiol Drug Saf; 2007 Jul; 16 Suppl 1():S2-S15. PubMed ID: 17546573
[TBL] [Abstract][Full Text] [Related]
11. The contribution of pharmacoepidemiology to the antidepressant-suicidality debate in children and adolescents.
Bridge JA; Axelson DA
Int Rev Psychiatry; 2008 Apr; 20(2):209-14. PubMed ID: 18386214
[TBL] [Abstract][Full Text] [Related]
12. The case-crossover study design in pharmacoepidemiology.
Delaney JA; Suissa S
Stat Methods Med Res; 2009 Feb; 18(1):53-65. PubMed ID: 18765504
[TBL] [Abstract][Full Text] [Related]
13. Packaging of pharmaceuticals: still too many dangers but several encouraging initiatives.
Prescrire Int; 2007 Jun; 16(89):126-8. PubMed ID: 17585428
[TBL] [Abstract][Full Text] [Related]
14. The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France.
Olivier P; Montastruc JL
Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):808-12. PubMed ID: 16700082
[TBL] [Abstract][Full Text] [Related]
15. Efficient sampling approaches to address confounding in database studies.
Hanley JA; Dendukuri N
Stat Methods Med Res; 2009 Feb; 18(1):81-105. PubMed ID: 18815164
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacoepidemiology: definition, methods and applications].
Montastruc JL; Sommet A; Montastruc F; Moulis G; Bagheri H; Damase-michel C; Lapeyre-mestre M
Bull Acad Natl Med; 2015; 199(2-3):263-73; discussion 273. PubMed ID: 27476308
[TBL] [Abstract][Full Text] [Related]
17. [Use of drugs in residents of homes for the elderly and nursing homes in comparison with patients in ambulatory care or without need of care].
Pittrow D; Krappweis J; Kirch W
Dtsch Med Wochenschr; 2002 Sep; 127(39):1995-2000. PubMed ID: 12324879
[TBL] [Abstract][Full Text] [Related]
18. Immortal time bias in pharmaco-epidemiology.
Suissa S
Am J Epidemiol; 2008 Feb; 167(4):492-9. PubMed ID: 18056625
[TBL] [Abstract][Full Text] [Related]
19. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
20. Interpretation of associations in pharmacoepidemiology.
Kaufman DW
Semin Hematol; 2008 Jul; 45(3):181-8. PubMed ID: 18582625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
